The PROTEUS trial found that adding apalutamide to hormone therapy (ADT) before and after surgery helped patients with high-risk prostate cancer. Patients who received apalutamide had a lower chance of their cancer spreading and were more likely to have little or no cancer left after surgery compared with those who received hormone therapy alone.
The treatment caused more side effects, such as hot flashes, joint pain, and skin rash, but most patients were able to complete treatment. Researchers believe this combination could become a new standard treatment for high-risk prostate cancer, although more studies are needed to determine which patients benefit the most and whether it helps people live longer.
This study could change how doctors treat high-risk prostate cancer. Instead of surgery alone, patients may soon receive hormone therapy plus apalutamide before and after surgery, which can reduce the risk of the cancer spreading. If future studies confirm these benefits, this approach could improve outcomes and give patients a better chance of long-term survival.
By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.
Are you a healthcare professional? Register with us today!
